NuPathe to Host Conference Call to Discuss Fourth Quarter and Full Year 2012 Results on Tuesday, March 26, 2013

NuPathe to Host Conference Call to Discuss Fourth Quarter and Full Year 2012 
Results on Tuesday, March 26, 2013 
CONSHOHOCKEN, PA -- (Marketwire) -- 03/19/13 --  NuPathe Inc.
(NASDAQ: PATH) will host a conference call on Tuesday, March 26,
2013, at 8:30 a.m. EDT to discuss fourth quarter and full year 2012
results and recent operational highlights. A question-and-answer
session will follow NuPathe's remarks. 
To participate on the live call, please dial 888-510-1786 (domestic)
or +1-719-325-2452 (international) and provide the participant
passcode 4967850 five to ten minutes before the start of the call. A
replay of the call will be available for 90 days within a few hours
after the call ends. Investors may listen to the replay of the call
by dialing 888-203-1112 (domestic) or +1-719-457-0820
(international), with the passcode 4967850. 
A live audio webcast of the call will be also available via the
"Investor Relations" page of the NuPathe website, www.nupathe.com.
Please log on through NuPathe's website approximately 10 minutes
before the scheduled start time. A replay of the webcast will be
archived on NuPathe's website for 90 days following the call. 
About NuPathe
 NuPathe Inc. is a specialty pharmaceutical company
focused on innovative neuroscience solutions for diseases of the
central nervous system including neurological and psychiatric
disorders. NuPathe's lead product, Zecuity (sumatriptan iontophoretic
transdermal system), has been approved by the FDA for the acute
treatment of migraine with or without aura in adults. In addition to
Zecuity, NuPathe has two proprietary product candidates based on its
LAD(TM), or Long-Acting Delivery, biodegradable implant technology
that allows delivery of therapeutic levels of medication over a
period of months with a single dose. NP201, for the continuous
symptomatic treatment of Parkinson's disease, utilizes a leading
FDA-approved dopamine agonist, ropinirole, and is being developed to
provide up to two months of continuous delivery. NP202, for the
long-term treatment of schizophrenia and bipolar disorder, is being
developed to address the long-standing problem of patient
noncompliance by providing three months of continuous delivery of
risperidone, an atypical antipsychotic. NuPathe is actively seeking
partnerships to maximize the commercial potential for Zecuity and its
other product candidates in the U.S. and territories throughout the
world. 
For more information about NuPathe, please visit our website at
www.nupathe.com. You can also follow us on StockTwits
(stocktwits.nupathe.com), Twitter (twitter.nupathe.com), SlideShare
(slideshare.nupathe.com) and LinkedIn (linkedin.nupathe.com). 
Contact Information: 
INVESTOR CONTACTS:
Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com 
Keith A. Goldan
Vice President, Chief Financial Officer
NuPathe Inc.
(484) 567-0130 
MEDIA CONTACT:
Sage Strategic Marketing
Jennifer Guinan
(610) 410-8111
jennifer@sagestrat.com